NeoMercazole 5mg Tablets
*Company:
ADVANZ PharmaStatus:
UpdatedLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 03 December 2025
File name
NeoMercazole 5 mg Tablets_PIL.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 03 December 2025
File name
1.3.1-SmPC-Brand-Famar-IE-English-0024-Neomercazole-5mg.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 04 November 2025
File name
NeoMercazol 5 mg & 20mg Tablets_PIL.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Updated on 04 November 2025
File name
NeoMercazole 5 mg Tablets_SPC.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 30 December 2021
File name
NeoMercazole tablets_PIL_IE.pdf
Reasons for updating
- New PIL for new product
Updated on 28 May 2021
File name
NeoMercazole 5 mg Tablets_SPC_IE.pdf
Reasons for updating
- Other
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
add desiccant in the primary pack i.e. bottle.
Updated on 06 August 2015
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 06 August 2015
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.8 was updated with the ADR statement
Updated on 06 August 2015
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Free text change information supplied by the pharmaceutical company
Section 4.8 was updated with the ADR statement
Updated on 23 July 2014
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section:-2. Qualitative and quantitative composition
Section:-4.1 Therapeutic indications
Section:-4.2 Posology and method of administration
Section:-4.3 Contraindications
Section:-4.4 Special warnings and precautions for use
Section:-4.5 Interaction with other medicinal products and other forms of interaction
Section:-4.6. Pregnancy and lactation
Section:-4.7 Effects on ability to drive and use machines
Section:-4.8 Undesirable effects
Section:-4.9 Overdose
Section:-5.1 Pharmacodynamic properties
Section:-5.2 Pharmacokinetic properties
Section:-5.3 Preclinical safety data
Section:-6.6 Special precautions for disposal and other handling
Section:-10. Date of revision of the text
Section:-4.1 Therapeutic indications
Section:-4.2 Posology and method of administration
Section:-4.3 Contraindications
Section:-4.4 Special warnings and precautions for use
Section:-4.5 Interaction with other medicinal products and other forms of interaction
Section:-4.6. Pregnancy and lactation
Section:-4.7 Effects on ability to drive and use machines
Section:-4.8 Undesirable effects
Section:-4.9 Overdose
Section:-5.1 Pharmacodynamic properties
Section:-5.2 Pharmacokinetic properties
Section:-5.3 Preclinical safety data
Section:-6.6 Special precautions for disposal and other handling
Section:-10. Date of revision of the text
Updated on 23 July 2014
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Section:-2. Qualitative and quantitative composition
Section:-4.1 Therapeutic indications
Section:-4.2 Posology and method of administration
Section:-4.3 Contraindications
Section:-4.4 Special warnings and precautions for use
Section:-4.5 Interaction with other medicinal products and other forms of interaction
Section:-4.6. Pregnancy and lactation
Section:-4.7 Effects on ability to drive and use machines
Section:-4.8 Undesirable effects
Section:-4.9 Overdose
Section:-5.1 Pharmacodynamic properties
Section:-5.2 Pharmacokinetic properties
Section:-5.3 Preclinical safety data
Section:-6.6 Special precautions for disposal and other handling
Section:-10. Date of revision of the text
Section:-4.1 Therapeutic indications
Section:-4.2 Posology and method of administration
Section:-4.3 Contraindications
Section:-4.4 Special warnings and precautions for use
Section:-4.5 Interaction with other medicinal products and other forms of interaction
Section:-4.6. Pregnancy and lactation
Section:-4.7 Effects on ability to drive and use machines
Section:-4.8 Undesirable effects
Section:-4.9 Overdose
Section:-5.1 Pharmacodynamic properties
Section:-5.2 Pharmacokinetic properties
Section:-5.3 Preclinical safety data
Section:-6.6 Special precautions for disposal and other handling
Section:-10. Date of revision of the text
Updated on 08 June 2011
Reasons for updating
- New individual SPC (was previously included in combined SPC)
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
None provided
Updated on 08 June 2011
Reasons for updating
- New individual SPC (was previously included in combined SPC)
Free text change information supplied by the pharmaceutical company
None provided
ADVANZ Pharma
Address:
Unit 17 Northwood House Northwood Crescent Northwood, Dublin 9, D09 V504, IrelandMedical Information E-mail:
medicalinformation@advanzpharma.comTelephone:
+44 (0)208 588 9131Website:
https://www.advanzpharma.comMedical Information Direct Line:
+353 1800 851 119Customer Care direct line:
+353 1 5294 230